APO Research
Talk to an analyst

APO RESEARCH · REPORT

PMO (Phosphorodiamidate Morpholino Oligomers) Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025183 pages

Choose your research edition.

Industry ResearchPMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PMO (Phosphorodiamidate Morpholino Oligomers) Drug include Avidity Biosciences, Dyne, Nippon Shinyaku, NS Pharma, Inc. and Sarepta Therapeutics, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PMO (Phosphorodiamidate Morpholino Oligomers) Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PMO (Phosphorodiamidate Morpholino Oligomers) Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the PMO (Phosphorodiamidate Morpholino Oligomers) Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Company

Avidity Biosciences

Dyne

Nippon Shinyaku

NS Pharma, Inc.

Sarepta Therapeutics, Inc

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Type

DMD exon 45 Based

DMD exon 51 Based

DMD exon 53 Based

Other

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Application

Hospital

Clinic

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PMO (Phosphorodiamidate Morpholino Oligomers) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of PMO (Phosphorodiamidate Morpholino Oligomers) Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug industry.

Chapter 3: Detailed analysis of PMO (Phosphorodiamidate Morpholino Oligomers) Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PMO (Phosphorodiamidate Morpholino Oligomers) Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of DMD exon 45 Based Table 3. Key Players of DMD exon 51 Based Table 4. Key Players of DMD exon 53 Based Table 3. Key Players of Other Table 4. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospital Table 6. Key Players of Clinic Table 7. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2021-2026) & (US$ Million) Table 9. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region (2021-2026) Table 10. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2027-2032) & (US$ Million) Table 11. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region (2027-2032) Table 12. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Trends Table 13. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Drivers Table 14. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Opportunities and Challenges Table 15. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Restraints Table 16. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Company (US$ Million) & (2021-2026) Table 17. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Company (2021-2026) Table 18. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Key Company Head Office and Area Served Table 20. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company, Product Type & Application Table 21. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026) & (US$ Million) Table 26. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2027-2032) & (US$ Million) Table 27. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Type (2021-2026) Table 28. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Type (2027-2032) Table 29. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026) & (US$ Million) Table 31. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2027-2032) & (US$ Million) Table 32. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Application (2021-2026) Table 33. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Application (2027-2032) Table 34. Avidity Biosciences Company Information Table 35. Avidity Biosciences Business Overview Table 36. Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 38. Avidity Biosciences Recent Development Table 39. Dyne Company Information Table 40. Dyne Business Overview Table 41. Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 43. Dyne Recent Development Table 44. Nippon Shinyaku Company Information Table 45. Nippon Shinyaku Business Overview Table 46. Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 48. Nippon Shinyaku Recent Development Table 49. NS Pharma, Inc. Company Information Table 50. NS Pharma, Inc. Business Overview Table 51. NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 53. NS Pharma, Inc. Recent Development Table 54. Sarepta Therapeutics, Inc Company Information Table 55. Sarepta Therapeutics, Inc Business Overview Table 56. Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 58. Sarepta Therapeutics, Inc Recent Development Table 59. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026) & (US$ Million) Table 60. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2027-2032) & (US$ Million) Table 61. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026) & (US$ Million) Table 62. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2027-2032) & (US$ Million) Table 63. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 64. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) Table 65. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032) Table 66. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026) & (US$ Million) Table 67. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2027-2032) & (US$ Million) Table 68. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026) & (US$ Million) Table 69. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2027-2032) & (US$ Million) Table 70. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 71. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) Table 72. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032) Table 73. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026) & (US$ Million) Table 74. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2027-2032) & (US$ Million) Table 75. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026) & (US$ Million) Table 76. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2027-2032) & (US$ Million) Table 77. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026) & (US$ Million) Table 78. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2027-2032) & (US$ Million) Table 79. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026) & (US$ Million) Table 80. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2027-2032) & (US$ Million) Table 81. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) Table 83. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032) Table 84. South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026) & (US$ Million) Table 85. South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2027-2032) & (US$ Million) Table 86. South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026) & (US$ Million) Table 87. South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2027-2032) & (US$ Million) Table 88. South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) Table 90. South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032) Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Image Figure 2. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type: 2025 VS 2032 Figure 4. DMD exon 45 Based Image Figure 5. DMD exon 51 Based Image Figure 6. DMD exon 53 Based Image Figure 7. Other Image Figure 8. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application: 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 14. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Players in 2025 Figure 17. Global Top 5 and 10 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Type (2021-2032) Figure 21. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Application (2021-2032) Figure 23. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 24. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type (2021-2032) Figure 25. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application (2021-2032) Figure 26. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032) Figure 27. United States PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 28. Canada PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 29. Mexico PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 30. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 31. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type (2021-2032) Figure 32. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application (2021-2032) Figure 33. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032) Figure 34. Germany PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 35. France PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 36. U.K. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 37. Italy PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 38. Russia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 40. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 41. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type (2021-2032) Figure 42. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application (2021-2032) Figure 43. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 44. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type (2021-2032) Figure 45. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application (2021-2032) Figure 46. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032) Figure 47. Japan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 48. South Korea PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 51. India PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 52. Australia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032) Figure 57. Brazil PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 58. South Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 60. Turkey PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 61. Argentina PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 62. UAE PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 63. Egypt PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 64. Chile PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • DMD exon 45 Based
  • DMD exon 51 Based
  • DMD exon 53 Based
  • Other
Applications
  • Hospital
  • Clinic
Companies covered
  • Avidity Biosciences
  • Dyne
  • Nippon Shinyaku
  • NS Pharma, Inc.
  • Sarepta Therapeutics, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 DMD exon 45 Based
  5. 1.2.3 DMD exon 51 Based
  6. 1.2.4 DMD exon 53 Based
  7. 1.2.5 Other
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Growth Trends by Region
  14. 1.5.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2021-2026)
  16. 1.5.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Dynamics
  1. 2.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Trends
  2. 2.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Drivers
  3. 2.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Opportunities and Challenges
  4. 2.4 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Company (2021-2026)
  2. 3.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Key Company Head office and Area Served
  4. 3.4 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company, Product Type & Application
  5. 3.5 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Tier 1, Tier 2, and Tier 3
4 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Type
  1. 4.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2032)
  3. 4.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Type (2021-2032)
5 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Application
  1. 5.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2032)
  3. 5.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Avidity Biosciences
  2. 6.1.1 Avidity Biosciences Company Information
  3. 6.1.2 Avidity Biosciences Business Overview
  4. 6.1.3 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  6. 6.1.5 Avidity Biosciences Recent Developments
  7. 6.2 Dyne
  8. 6.2.1 Dyne Company Information
  9. 6.2.2 Dyne Business Overview
  10. 6.2.3 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  12. 6.2.5 Dyne Recent Developments
  13. 6.3 Nippon Shinyaku
  14. 6.3.1 Nippon Shinyaku Company Information
  15. 6.3.2 Nippon Shinyaku Business Overview
  16. 6.3.3 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  18. 6.3.5 Nippon Shinyaku Recent Developments
  19. 6.4 NS Pharma, Inc.
  20. 6.4.1 NS Pharma, Inc. Company Information
  21. 6.4.2 NS Pharma, Inc. Business Overview
  22. 6.4.3 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  24. 6.4.5 NS Pharma, Inc. Recent Developments
  25. 6.5 Sarepta Therapeutics, Inc
  26. 6.5.1 Sarepta Therapeutics, Inc Company Information
  27. 6.5.2 Sarepta Therapeutics, Inc Business Overview
  28. 6.5.3 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  30. 6.5.5 Sarepta Therapeutics, Inc Recent Developments
7 North America
  1. 7.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
  2. 7.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type
  3. 7.2.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type (2021-2032)
  6. 7.3 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application
  7. 7.3.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application (2021-2032)
  10. 7.4 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country
  11. 7.4.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
  2. 8.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type
  3. 8.2.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type (2021-2032)
  6. 8.3 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application
  7. 8.3.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application (2021-2032)
  10. 8.4 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country
  11. 8.4.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
  2. 9.2 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type
  3. 9.2.1 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026)
  4. 9.2.2 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2027-2032)
  5. 9.2.3 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type (2021-2032)
  6. 9.3 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application
  7. 9.3.1 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026)
  8. 9.3.2 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2027-2032)
  9. 9.3.3 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
  2. 10.2 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type
  3. 10.2.1 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type (2021-2032)
  6. 10.3 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application
  7. 10.3.1 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application (2021-2032)
  10. 10.4 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country
  11. 10.4.1 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst